JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy

Gremese, E., Alivernini, S., Tolusso, B. et al. (2 more authors) (2019) JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. Journal of Leukocyte Biology, 106 (5). pp. 1063-1068. ISSN 0741-5400

Abstract

Metadata

Authors/Creators:
  • Gremese, E.
  • Alivernini, S.
  • Tolusso, B.
  • Zeidler, M.P.
  • Ferraccioli, G.
Copyright, Publisher and Additional Information: © 2019 The Authors. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License(https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
Keywords: adenosine; JAK inhibition; Methotrexate
Dates:
  • Accepted: 23 June 2019
  • Published (online): 16 July 2019
  • Published: 1 November 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Science (Sheffield) > School of Biological Sciences (Sheffield) > Department of Biomedical Science (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 18 Nov 2019 15:26
Last Modified: 18 Nov 2019 15:26
Status: Published
Publisher: Wiley
Refereed: Yes
Identification Number: https://doi.org/10.1002/jlb.5ru0519-145r

Share / Export

Statistics